MEA Bladder Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.60 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
MEA Bladder Cancer Therapeutics & Diagnostics Market Analysis
The bladder cancer therapeutics and diagnostics market will witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing innovation in drug development. Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. In countries in the Middle East and Africa (MEA) region like the United Arab Emirates (UAE), the bladder cancer is 8th most common type of cancer, as per Globocan 2018 data.
In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Middle East and Africa. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.
Hence, the increasing awareness about bladder cancer and related therapies, the Middle East and Africa bladder cancer therapeutics and diagnostics market is expected to grow in the coming future.
MEA Bladder Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the MEA Bladder Cancer Therapeutics & Diagnostics Market according to our research experts:
Radiation Therapy is Expected to Cover a Large Share of the Market
Bladder cancer is highly prevalent diseases and it increases with age. As per a 2018 Globocan report, the bladder cancer incidence in the Middle East and Africa region is expected to increase in the future. The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also, offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Advancements in radiation therapy and expected increase in number of bladder cancer patients is expected to help the growth of this market.
MEA Bladder Cancer Therapeutics & Diagnostics Industry Overview
Most of the global players are present in the Gulf Cooperation Council (GCC) region of the Middle East and Africa (MEA) owing to factors such as economic growth in the last few decades.
The Africa region consists of some developing and underdeveloped countries. The healthcare systems in these countries are still not well structured and stable, due to the lack of essential funds. However, with recent foreign investments, the healthcare scenario is improving in the region. Hence the market in this region, though not large, is expected to grow in the future.
MEA Bladder Cancer Therapeutics & Diagnostics Market Leaders
-
Pfizer Inc.
-
Johnson and Johnson
-
AstraZeneca Plc.
-
Bristol Myers Squibb
-
Merck & Co., Inc.
*Disclaimer: Major Players sorted in no particular order
MEA Bladder Cancer Therapeutics & Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
- 4.2.2 Innovations in Drug Development
-
4.3 Market Restraints
- 4.3.1 Rise in the number of Patent Expirations
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
- 5.1.1 Transitional Cell Bladder Cancer
- 5.1.2 Superficial Bladder Cancer
- 5.1.3 Invasive Bladder Cancer
- 5.1.4 Other Rare Types
-
5.2 By Diagnostics and Therapeutics
- 5.2.1 By Therapeutics
- 5.2.1.1 Chemotherapy
- 5.2.1.2 Immunotherapy
- 5.2.1.3 Radiation Therapy
- 5.2.1.4 Surgery
- 5.2.2 By Diagnostics
- 5.2.2.1 Cytoscopy
- 5.2.2.2 Biopsy
- 5.2.2.3 Urinalysis
- 5.2.2.4 Others
-
5.3 Geography
- 5.3.1 Middle East and Africa
- 5.3.1.1 GCC
- 5.3.1.2 South Africa
- 5.3.1.3 Rest of Middle East and Africa
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AstraZeneca Plc.
- 6.1.2 Bristol Myers Squibb
- 6.1.3 Eli Lilly and Co.
- 6.1.4 GlaxoSmithKline Plc.
- 6.1.5 Merck & Co., Inc.
- 6.1.6 Johnson and Johnson
- 6.1.7 Novartis AG
- 6.1.8 Pfizer Inc.
- 6.1.9 Sanofi S.A.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
MEA Bladder Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market.
| By Cancer Type | Transitional Cell Bladder Cancer | |
| Superficial Bladder Cancer | ||
| Invasive Bladder Cancer | ||
| Other Rare Types | ||
| By Diagnostics and Therapeutics | By Therapeutics | Chemotherapy |
| Immunotherapy | ||
| Radiation Therapy | ||
| Surgery | ||
| By Diagnostics and Therapeutics | By Diagnostics | Cytoscopy |
| Biopsy | ||
| Urinalysis | ||
| Others | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa |
MEA Bladder Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current MEA Bladder Cancer Therapeutics & Diagnostics Market size?
The MEA Bladder Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)
Who are the key players in MEA Bladder Cancer Therapeutics & Diagnostics Market?
Pfizer Inc., Johnson and Johnson, AstraZeneca Plc., Bristol Myers Squibb and Merck & Co., Inc. are the major companies operating in the MEA Bladder Cancer Therapeutics & Diagnostics Market.
What years does this MEA Bladder Cancer Therapeutics & Diagnostics Market cover?
The report covers the MEA Bladder Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the MEA Bladder Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
MEA Bladder Cancer Therapeutics & Diagnostics Industry Report
Statistics for the 2024 MEA Bladder Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MEA Bladder Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
